Moriah M. Mitchell

Moriah M. Mitchell

Auto-generated profile, based on publicly available information

Moriah M. Mitchell

Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2018 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SCStefano Costanzi
Stefano Costanzi
JMJohn-Hanson Machado
John-Hanson Machado
MMMoriah Mitchell
Moriah Mitchell

26 July 2023 in Science Translational Medicine
Verified
Journal Article
Open access
MMMoriah M. Mitchell
Moriah M. Mitchell
YLYumei Leng
Yumei Leng
SBSuresh Boppana
Suresh Boppana
WBWilliam J. Britt
William J. Britt
LSLuz Helena Gutierrez Sanchez
Luz Helena Gutierrez Sanchez
SEStephen J. Elledge
Stephen J. Elledge
Severe acute hepatitis of unknown etiology in children is under investigation in 35 countries. Although several potential etiologic agents have been investigated, a clear cause for the liver damage observed in these cases remains to be identified. Using VirScan, a high-throughput antibody profiling technology, we probed the antibody repertoires of nine cases of severe acute hepatitis of unknown etiology treated at Children’s of Alabama and compared their antibody responses with 38 pediatric and 470 adult controls. We report increased adeno-associated dependoparvovirus A (AAV-A) breadth in cases relative to controls and adeno-associated virus 2 (AAV-2) peptide responses that were conserved in seven of nine cases but rarely observed in pediatric and adult controls. These findings suggest that AAV-2 is a likely etiologic agent of severe acute hepatitis of unknown etiology.

22 June 2026 in Nature Communications
Verified
Journal Article
Open access
MMMoriah M. Mitchell
Moriah M. Mitchell
TKTomasz Kula
Tomasz Kula
JRJennifer L. Remmel
Jennifer L. Remmel
SXSiyang Xia
Siyang Xia
ESEllen L. Shrock
Ellen L. Shrock
SEStephen J. Elledge
Stephen J. Elledge
The human antiviral antibody reactome provides a cumulative molecular record of immune exposures. Using high-resolution VirScan profiling, we compared epitope-level antibody responses across early childhood and adulthood. Infants are born with maternal IgG antibodies, but these antibodies decay rapidly and are replaced by endogenous responses to ~22 new viral exposures within three years. Pediatric antibody reactivities remain highly dynamic until about age 7 and are broad in epitope specificity but largely short-lived. In contrast, adult reactomes are remarkably stable and individualized, enabling accurate longitudinal donor identification (Immunoprint, > 99.99% accuracy). Stability varies by viral family, with Pneumoviridae and Picornaviridae persisting more robustly than Coronaviridae or Orthomyxoviridae . Across ages, immunodominant epitopes and initial binding strength predict response persistence. Longitudinal profiling highlights biological and epidemiological drivers of reactome change. This population-level, age-stratified atlas informs our understanding of immune memory and development with applications to vaccine design, surveillance, and precision public health.